Several clinical studies are currently ongoing within the I-BFM SG

The I-BFM Study Group is actively engaged in several clinical studies aimed at advancing treatment for pediatric leukemias and lymphomas. Below, you’ll find brief summaries of some of the key studies currently underway, highlighting the group’s ongoing efforts to improve outcomes for young patients.

 

ALL

  • AIEOP-BFM ALL 2017 (2017 – )

    Randomized clinical trial for ALL (age 1-18y)

  • ALL-IC 2022 (3/2023 – )

    Randomized clinical trial for ALL in countries with limited resources

  • ALLTogether-1 (2021 – )

    Randomized clinical trial for ALL (age up to 45 years)

  • EsPhALL2017-COGAALL1631

    Randomized trial for patients with Ph+ ALLAIEOP-BFM ALL 2017 (2017-2023): Randomized clinical trial (age 1.0-21.9y)

  • Interfant-21 (2/2023 – )

    Non-randomized clinical trial for all pts under 1y of age with KMT2A rear. ALL

AML

  • AAML1831

    Frontline protocol (COG)

  • AIEOP-AML-BFM 2020

    Frontline protocol (BFM, AIEOP)

  • AMoRe 2017

    For molecular relapsed AML patients

  • EuPAL trials

    For relapsed AML patients and early phase trials for relapsed AML (ITCC)

  • ICC APL study 02

    For newly diagnosed APL patients

  • JPLSG-AML-20

    Frontline protocol (JCCG)

  • JPLSG-AML-D16

    For newly diagnosed Down syndrome patients with myeloid leukemia (JCCG)

  • JPLSG-AML-P13

    For newly diagnosed APL patients (JCCG)

  • ML-DS 2018

    For newly diagnosed Down syndrome patients with myeloid leukemia

  • MyeChild01

    Frontline protocol (SFCE, CCLG, Ireland, Australia, Switzerland)

  • NOPHO-DBH AML 2012

    Frontline protocol (NOPHO DH SHIP)

  • PedAL trials

    For relapsed AML patients and early phase trials for relapsed AML (COG)

CML

  • Asciminib CABL001I12201 – ASC4KIDS

  • Bosutinib Study ITCC-054/AAML1921

  • Ponatinib Paediatric INCB84344-102 Study

ELTEC

Projects in close collaboration with other committees in the field of early toxicity:

  • Middle and late term toxicity in ALL

  • Prevention, Diagnosis & Management of Thrombosis & Bleeding in Children with Acute Lymphoblastic Leukaemia: European Survey of Current Practice

  • Supportive care in leukaemia treatment

  • Toxicity issues in NHL

Projects in the field of late toxicity inside I-BFM:

  • Survey on your knowledge about your disease and later care

Projects in the field of late toxicity in collaboration with PanCare:

  • PanCareLife

  • Survivorship Passport

NHL

  • EICNHL trial

    ALCL-VBL study in SR ALK-pos. ALCL

  • EICNHL/i-BFM trial

    LBL 2018 study in lymphoblastic lymphoma

  • NHL-BFM and NOPHO trial

    B-NHL 2013 study in mature B-cell neoplasms

SCT

ALL SCT PED 2012 Forum (for omitting radiation under majority age). Allogeneic Stem Cell Transplantation in Children and Adolescents with ALL in CR. Prospective controlled randomized international study:

  • Principal investigator: Christina Peters, E-mail: peters@stanna.at
  • Participating countries: Austria, Argentina, Australia, Chile, Czech Republic. Denmark, Finland, France, Germany, Greece, Hong-Kong, Hungary, Japan, Israel, Italy, The Netherlands, New Zealand, Norway, Polland, Slovakia, Sweden, Spain, Switzerland, Turkey, United Kingdom, USA
  • The study is open for international recruitment. Randomization is closed.